首页> 外文期刊>Clinical and experimental dermatology >Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids.
【24h】

Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids.

机译:英夫利昔单抗治疗后顽固性顽固性角膜下脓疱性皮肤病(Sneddon-Wilkinson病)的早期但不是持久的改善:与抽吸水疱液中细胞因子水平变化的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Summary Subcorneal pustular dermatosis (SCPD) is an uncommon disorder, characterized by a chronic relapsing vesiculopustular eruption, mainly involving the trunk and intertriginous areas, and usually seen in women > 40 years old. Various therapies have been reported to be effective in treating SCPD, such as dapsone, systemic glucocorticoids, acitretin, etretinate, infliximab and phototherapy. We report a case of a 54-year-old woman affected by SCPD who after failure of different therapies showed a dramatic but only temporary improvement of her disease during a cycle of therapy with infliximab. In addition, an array of cytokines was simultaneously measured in suction blister fluids obtained from involved or uninvolved skin at various time intervals during the first 12 weeks of observation.
机译:总结角膜下脓疱性皮肤病(SCPD)是一种罕见的疾病,其特征是慢性复发性囊泡性皮疹,主要累及躯干和三尖瓣区,通常见于40岁以上的女性。据报导各种疗法可有效治疗SCPD,例如氨苯砜,全身性糖皮质激素,阿维A,维甲酸,英夫利昔单抗和光疗。我们报道了一例54岁的受SCPD影响的妇女,在使用不同的疗法失败后,英夫利昔单抗治疗周期显示出她的疾病有了显着但暂时的改善。此外,在观察的前12周内,在不同时间间隔同时测量了从受累或未受累皮肤获得的吸水疱液中的一系列细胞因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号